Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 108Ovarian Neoplasms 64Neoplasms 61Fallopian Tube Neoplasms 40Lung Neoplasms 37Breast Neoplasms 33Neoplasm Metastasis 25Carcinoma, Ovarian Epithelial 25Triple Negative Breast Neoplasms 21Small Cell Lung Carcinoma 20Esophageal Neoplasms 19Endometrial Neoplasms 19Colorectal Neoplasms 15Advanced Solid Tumors 14Squamous Cell Carcinoma of Head and Neck 13Lymphoma, Large B-Cell, Diffuse 13Unspecified Adult Solid Tumor, Protocol Specific 12Stomach Neoplasms 11Melanoma 11Central Nervous System Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 10Astrocytoma 10Neuroblastoma 9Medulloblastoma 9Head and Neck Neoplasms 9Carcinoma 9Urinary Bladder Neoplasms 8Solid Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

palbociclib 1defactinib 1adavosertib 1Taxes 1Radiation 1RO5126766 1Platinum 1Paclitaxel 1Fulvestrant 1Dasatinib 1Congresses as Topic 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Endometrioid × Carboplatin × Clear all
NCT01440998 2018-04-05

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 1 Completed
18 enrolled

Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡